Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.48 |
| ▸ | PPARD | Q03181 | 9/20 | 0.48 |
| ▸ | PPARG | P37231 | 10/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474756 | 0.81 | PPARA (0.67) | PPARAPPARDPPARGCYP2C9KCNH2 | |
| SCHEMBL4486991 | 0.78 | PPARA (0.54) | PPARAPPARDPPARG | |
| SCHEMBL4485700 | 0.77 | PPARD (0.58) | PPARAPPARDPPARG | |
| SCHEMBL3505941 | 0.76 | PPARG (0.58) | PPARAPPARGCYP2C9KCNH2PTPN1 | |
| SCHEMBL4674437 | 0.76 | PPARG (0.69) | PPARAPPARGCYP2C9KCNH2PTPN1 | |
| SCHEMBL4462711 | 0.76 | PPARA (0.64) | PPARAPPARDPPARG | |
| SCHEMBL4473563 | 0.75 | PPARD (0.53) | PPARAPPARDPPARG | |
| SCHEMBL4473559 | 0.75 | PPARD (0.53) | PPARAPPARDPPARG | |
| SCHEMBL4486426 | 0.75 | PPARD (0.53) | PPARAPPARDPPARG | |
| SCHEMBL5761603 | 0.75 | KDM4E (0.70) | PPARAPPARDPPARGCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | claimed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | claimed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | claimed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | PPARA 2/4885PPARD 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.